Commentary: GSK, Pfizer and GE shift away from diversification in latest round of health-care deals

The shift to focus on core businesses will enable health care giants to excel in their respective fields with increased market share, more efficient use of assets and increased return to shareholders. Their investors have already signaled that this is precisely what they want.